The assessment of the mental state of patients during simultaneous treatment with psychotropic drugs, antipsychotics included, and bromocriptine;Ocena stanu psychicznego pacjentek w trakcie jednoczesnego stosowania leków psychotropowych, w tym leków przeciwpsychotycznych, oraz bromokryptyny

Psychiatria Polska

Volumn 42, Issue 4, 2008, Pages 595-607

  Barszcz, Zbigniew ^a,d   Mucha, Sławomir ^b   Rabe Jabłońska, Jolanta ^c  

^a Centralny Szpital Kliniczny UM ^*  (Poland)

^b Klinika Endokrynologii UM   (Poland)

^c Klinika Zaburze Afektywnych I Psychotycznych UM   (Poland)

^d Centralny Szpital Kliniczny UM   (Poland)

Author keywords

Bromocriptine; Hyperprolactinemia; Psychotropic drugs

Indexed keywords

BROMOCRIPTINE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PROLACTIN; PSYCHOTROPIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; FEMALE; GALACTORRHEA; HAMILTON SCALE; HUMAN; HYPERPROLACTINEMIA; MENSTRUATION DISORDER; MENTAL HEALTH; NEUROLOGIC EXAMINATION; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; PARANOID SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BROMOCRIPTINE; COGNITION; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERPROLACTINEMIA; PROLACTIN; SCHIZOPHRENIA, PARANOID; TREATMENT OUTCOME; YOUNG ADULT;

EID: 61749084118     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Pawlikowski M. Choroby układu podwzgórzowo-przysadkowego. W: Pawlikowski M, red. Zarys endokrynologii klinicznej. Warszawa: PZWL; 1996, s. 25-45.
2. Beumont P, Bruwer J, Pimstone B, Vinik A, Utian W. Brom-ergocryptine in the treatment of phenothiazine-induced galactorrhoea. Brit. J. Psychiatry 1975; 126: 285-288.
3. Cohn JB, Brust J, DiSerio F, Singer J. Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment. Neuropsychobiol. 1985; 13 (4): 173-179.
4. Matsuoka I, Nakai T, Miyake M, Hirai M, Ikawa G. Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence. J. Psychiatr. Neurol. 1986; 40 (4): 639-646.
5. Smith S. Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J. Reprod. Med. 1992; 37 (8): 737-740.
6. Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J. Child Adolesc. Psychopharmacol. 2001; 11 (4): 435-440.
7. Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J. Clin. Psychiatry 2004; 65 (2): 187-189.
8. Correa N, Opler LA, Kay SR, Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J. Clin. Psychopharmacol. 1987; 7 (2): 91-95.
9. Shenoy RS, Ettigi P, Johnson CH. Bromocriptine in the treatment of galactorrhea caused by haloperidol: a case study. J. Clin. Psychopharmacol. 1983; 3 (3): 187-188.
10. Wolf R. Use of bromocriptine to prevent puerperal lactation during neuroleptic treatment of chronic schizophrenia. Pharmacopsychiatry 1992; 25 (5): 240-242.
11. Varia IM, Cavenar JO Jr, Taska RJ, Maltbie AA. Bromocriptine in the treatment of haloperidol-induced galactorrhea. N. C. Med. J. 1982; 43 (11): 769-770.
12. Popli A, Gupta S, Rangwani SR. Risperidone-induced galactorrhea associated with a prolactin elevation. Ann. Clin. Psychiatry 1998; 10 (1): 31-33.
13. Dorevitch A, Aronzon R, Stark M. Psychotic exacerbation attributed to low-dose bromocriptine treatment of galactorrhea and hyperprolactinemia. Acta Obstet. Gynecol. Scand. 1991; 70 (4-5): 375-376.
14. Pertegaz IB, Alberdi JMG, Rodon EP. Is cabergoline a better drug to inhibit lactation in patients with psychotic symptoms? Rev. Psychiatr. Neurosc. 2002; 27 (1): 54.
15. Carlsson A. Does dopamine have a role in schizophrenia? Biol. Psychiatry 1978; 13 (1): 3-21.
16. Snyder SH. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am. J. Psychiatry 1976; 133 (2): 197-202.
17. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr. Res. 1999; 1 (supl. 35): 75-86.
18. Perovich RM, Lieberman JA, Fleischhacker WW, Alvir J. The behavioral toxicity of bromocriptine in patients with psychiatric illness. J. Clin. Psychopharmacol. 1989; 9 (6): 417-422.
19. Pużyński S, Wciórka J. Narzȩdzia oceny stanu psychicznego. W: Bilikiewicz A, red. Psychiatria. Tom I: Podstawy psychiatrii. Wrocław: Urban & Partner; 2002, s. 453-526.